tiprankstipranks
Advertisement
Advertisement
Kura reports data supporting darlifarnib potential for KRAS-mutant cancers
PremiumThe FlyKura reports data supporting darlifarnib potential for KRAS-mutant cancers
15d ago
Kura Oncology reports first-in-human data from the FIT-001 clinical trial
Premium
The Fly
Kura Oncology reports first-in-human data from the FIT-001 clinical trial
23d ago
Kura Oncology: Buy Rating Reiterated as Early Darlifarnib/Adagrasib Data Support Favorable Risk-Reward and $40 Price Target Maintained
Premium
Ratings
Kura Oncology: Buy Rating Reiterated as Early Darlifarnib/Adagrasib Data Support Favorable Risk-Reward and $40 Price Target Maintained
27d ago
Kura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial
PremiumThe FlyKura, Kyowa Kirin to present updated frontline data from Phase 1 KOMET-007 trial
1M ago
Kura Oncology: Early Darlifarnib Kidney Cancer Data Validate FTI Strategy and Underscore Attractive Risk‑Reward Upside
Premium
Ratings
Kura Oncology: Early Darlifarnib Kidney Cancer Data Validate FTI Strategy and Underscore Attractive Risk‑Reward Upside
2M ago
Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating
Premium
Ratings
Kura Oncology: Compelling Darlifarnib–Cabozantinib Data in Post-IO RCC Support Continued Buy Rating
2M ago
Kura Oncology price target lowered to $25 from $30 at Mizuho
PremiumThe FlyKura Oncology price target lowered to $25 from $30 at Mizuho
3M ago
Kura Oncology price target lowered to $15 from $16 at UBS
Premium
The Fly
Kura Oncology price target lowered to $15 from $16 at UBS
3M ago
Kura Oncology price target raised to $30 from $29 at BofA
Premium
The Fly
Kura Oncology price target raised to $30 from $29 at BofA
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100